Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

European Ombudsman

- PMLiVE

EMA to review safety of Ariad’s Iclusig

Product information will be updated to warn of blood clot risk

- PMLiVE

EMA on track with biosimilars guidance says industry

Updates expected to build confidence among healthcare professionals and patients

- PMLiVE

EMA publishes European drug shortage details

First public list contains details on Cerezyme, Fabrazyme, Increlex and Vistide

- PMLiVE

CHMP names France’s Pierre Demolis vice-chair

He is director of the oncology and haematology division at the ANSM

- PMLiVE

Novo Nordisk recalls insulin

Batches of prefilled NovoMix 30 pens found to have incorrect amount of diabetes treatment

- PMLiVE

EMA backs Lundbeck’s Brintellix in depression

Drug recommended for approval to treat major depressive episodes in adults

- PMLiVE

Leo Pharma plans to share trial data from 2014

"It is the right thing to do" says UK managing director

- PMLiVE

EMA defends position on patient-level data

Regulator claims pharma industry fears over transparency are unfounded

- PMLiVE

J&J files HIV combination in Europe

Seeks approval for fixed-dose tablet containing Prezista and Gilead’s cobicistat

- PMLiVE

Orexigen files obesity drug in EU

Company expects Contrave to show positive cardiovascular safety 

- PMLiVE

EU launches black triangle drug monitoring scheme

New pharmacovigilance symbol will be used by all drugs needing additional monitoring

- PMLiVE

AZ moves closer to EU approval for ovarian cancer drug

Olaparib on course to be first PARP inhibitor available for ovarian cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links